دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Practical Advice on Surviving and Thriving as an Academic Physician-Neuroscientist
Juliet K. Knowles, MD, PhD1; Brenda E. Porter, MD, PhD1
doi : 10.1001/jamaneurol.2021.3889
JAMA Neurol. 2021;78(12):1439-1440
Full Circle
Allison Ho Kay, MD1
doi : 10.1001/jamaneurol.2021.3909
JAMA Neurol. 2021;78(12):1441-1442
Citius, Fortius, Altius—Understanding Which Components Drive Exercise Benefits in Parkinson Disease
Nienke M. de Vries, PhD1,2; Sirwan K. L. Darweesh, MD, PhD1,2; Bastiaan R. Bloem, MD, PhD1,2
doi : 10.1001/jamaneurol.2021.3744
JAMA Neurol. 2021;78(12):1443-1445
Association of Physical Activity, Including Amount and Maintenance, With All-Cause Mortality in Parkinson Disease
Seo Yeon Yoon, MD, PhD1; Jee Hyun Suh, MD, PhD2; Seung Nam Yang, MD, PhD1; Kyungdo Han, PhD3; Yong Wook Kim, MD, PhD4
doi : 10.1001/jamaneurol.2021.3926
JAMA Neurol. 2021;78(12):1446-1453
The protective effects of physical activity (PA) against Parkinson disease (PD) development have been suggested; however, the association of PA with mortality in PD has rarely been investigated.
Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin
Alexander E. Merkler, MD, MS1,2; Lesly A. Pearce, MS3; Scott E. Kasner, MD4; Ashkan Shoamanesh, MD5; Lee A. Birnbaum, MD6; Hooman Kamel, MD, MS1,2; Kevin N. Sheth, MD7; Richa Sharma, MD, MPH7
doi : 10.1001/jamaneurol.2021.3828
JAMA Neurol. 2021;78(12):1454-1460
It is uncertain whether anticoagulation is superior to aspirin at reducing recurrent stroke in patients with recent embolic strokes of undetermined source (ESUS) and left ventricular (LV) dysfunction.
Long-term Risk of Parkinson Disease Following Influenza and Other Infections
Noelle M. Cocoros, DSc, MPH1; Elisabeth Svensson, PhD2,3; Szimonetta Komjáthine Szépligeti, MSc2; Søren Viborg Vestergaard, MD2; Péter Szentkúti, MSc2; Reimar W. Thomsen, MD, PhD2; Per Borghammer, MD, PhD, DMSc4; Henrik Toft Sørensen, MD, PhD, DMSc, DSc2,5; Victor W. Henderson, MD, MS2,6,7
doi : 10.1001/jamaneurol.2021.3895
JAMA Neurol. 2021;78(12):1461-1470
Influenza has been associated with the risk of developing Parkinson disease, but the association is controversial.
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
Andréa L. Benedet, PhD1,2; Marta Milà-Alomà, MSc3,4,5,6; Agathe Vrillon, MD, MSc1,7,8; Nicholas J. Ashton, PhD1,9,10,11; Tharick A. Pascoal, MD, PhD2; Firoza Lussier, BSc2; Thomas K. Karikari, PhD1; Claire Hourregue, MD8; Emmanuel Cognat, MD, PhD7,8; Julien Dumurgier, MD, PhD8; Jenna Stevenson, BSc2; Nesrine Rahmouni, BSc2; Vanessa Pallen, BSc2; Nina M. Poltronetti, MSc2; Gemma Salvadó, PhD3,4; Mahnaz Shekari, MSc3,4,6; Gregory Operto, PhD3,4,5; Juan Domingo Gispert, PhD3,4,6,12; Carolina Minguillon, PhD3,4,5; Karine Fauria, PhD3,5; Gwendlyn Kollmorgen, PhD13; Ivonne Suridjan, PhD14; Eduardo R. Zimmer, PhD15; Henrik Zetterberg, MD, PhD1,16,17,18; José Luis Molinuevo, MD, PhD3,4,5; Claire Paquet, MD, PhD7,8; Pedro Rosa-Neto, MD, PhD2,19,20; Kaj Blennow, MD, PhD1,16; Marc Suárez-Calvet, MD, PhD3,4,5,21; for the Translational Biomarkers in Aging and Dementia (TRIAD) study, Alzheimer’s and Families (ALFA) study, and BioCogBank Paris Lariboisière cohort
doi : 10.1001/jamaneurol.2021.3671
JAMA Neurol. 2021;78(12):1471-1483
Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease (AD). However, it is not known whether there are differences in blood GFAP levels across the entire AD continuum and whether its performance is similar to that of CSF GFAP.
Association Between Increased Seizures During Rewarming After Hypothermia for Neonatal Hypoxic Ischemic Encephalopathy and Abnormal Neurodevelopmental Outcomes at 2-Year Follow-up
Lina F. Chalak, MD, MSCS1; Athina Pappas, MD2; Sylvia Tan, MS3; Abhik Das, PhD4; Pablo J. Sánchez, MD5; Abbot R. Laptook, MD6; Krisa P. Van Meurs, MD7; Seetha Shankaran, MD2; Edward F. Bell, MD8; Alexis S. Davis, MD, MSEpi7; Roy J. Heyne, MD9; Claudia Pedroza, PhD10; Brenda B. Poindexter, MD, MS11,12; Kurt Schibler, MD13; Jon E. Tyson, MD, MPH14; M. Bethany Ball, BS, CCRC7; Rebecca Bara, RN, BSN2; Cathy Grisby, BSN13; Gregory M. Sokol, MD11; Carl T. D’Angio, MD15; Shannon E. G. Hamrick, MD12; Kevin C. Dysart, MD16; C. Michael Cotten, MD, MHS17; William E. Truog, MD18; Kristi L. Watterberg, MD19; Christopher J. Timan, MD5; Meena Garg, MD20; Waldemar A. Carlo, MD21; Rosemary D. Higgins, MD22; for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network
doi : 10.1001/jamaneurol.2021.3723
JAMA Neurol. 2021;78(12):1484-1493
Compared with normothermia, hypothermia has been shown to reduce death or disability in neonatal hypoxic ischemic encephalopathy but data on seizures during rewarming and associated outcomes are scarce.
Association of White Matter Hyperintensities With Pathology and Progression of Parkinsonism in Aging
Shahram Oveisgharan, MD1,2; Lei Yu, PhD1,2; Victoria N. Poole, PhD1,3,4; Arnold M. Evia, PhD1,3; Lisa L. Barnes, PhD1,2,5; Julie A. Schneider, MD1,2,6; Konstantinos Arfanakis, PhD1,3,7; David A. Bennett, MD1,2; Aron S. Buchman, MD1,2
doi : 10.1001/jamaneurol.2021.3996
JAMA Neurol. 2021;78(12):1494-1502
Progressive parkinsonism is common in older adults without a diagnosis of Parkinson disease and is associated with adverse health outcomes, but its pathologic basis is controversial.
Anti–SARS-CoV-2 and Autoantibody Profiles in the Cerebrospinal Fluid of 3 Teenaged Patients With COVID-19 and Subacute Neuropsychiatric Symptoms
Christopher M. Bartley, MD, PhD1,2,3; Claire Johns, MD4; Thomas T. Ngo, BS2,3; Ravi Dandekar, MS2,5; Rita L. Loudermilk, BS2,5; Bonny D. Alvarenga, BA2,5; Isobel A. Hawes, BA2,5,6; Colin R. Zamecnik, PhD2,5; Kelsey C. Zorn, MHS7; Jessa R. Alexander, BA2,5; Anne E. Wapniarski, BA2,5; Joseph L. DeRisi, PhD7,8; Carla Francisco, MD2,5; Kendall B. Nash, MD2,4,5; Sharon O. Wietstock, MD2,5; Samuel J. Pleasure, MD, PhD2,5; Michael R. Wilson, MD2,5
doi : 10.1001/jamaneurol.2021.3821
JAMA Neurol. 2021;78(12):1503-1509
Neuropsychiatric manifestations of COVID-19 have been reported in the pediatric population.
Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab
Livnat Brill, PhD1; Ariel Rechtman, BSc1; Omri Zveik, BMedSc1; Nitzan Haham, BMedSc1; Esther Oiknine-Djian, PhD2,3; Dana G. Wolf, MD, PhD2,3; Netta Levin, MD, PhD1; Catarina Raposo, PhD4; Adi Vaknin-Dembinsky, MD, PhD1
doi : 10.1001/jamaneurol.2021.3599
JAMA Neurol. 2021;78(12):1510-1514
B-cell–depleting therapies may affect the development of a protective immune response following vaccination. Understanding the ability to develop vaccine-specific immunity to COVID-19 in patients with multiple sclerosis (MS) treated with B-cell–depleting therapy is of importance for clinical decisions.
Health Disparities, Inequities, and Social Determinants of Health in Multiple Sclerosis and Related Disorders in the US
Lilyana Amezcua, MD, MS1; Victor M. Rivera, MD2; Teresa Corona Vazquez, MD3; Lourdes Baezconde-Garbanati, PhD4; Annette Langer-Gould, MD, PhD5
doi : 10.1001/jamaneurol.2021.3416
JAMA Neurol. 2021;78(12):1515-1524
There is empirical evidence that social determinants of health (SDOH) impact health outcomes in Black and Hispanic and Latinx individuals in the US. Recently, SDOH have risen to the top as essential intervention targets that could help alleviate racial and ethnic disparities. Neuromyelitis optica spectrum disorder (NMOSD) disproportionately affects Black individuals, and multiple sclerosis (MS) has seen a recent shift in select racial groups. It is unclear to what degree SDOH have been investigated and contribute to racial and ethnic health disparities and inequities.
Changes in Blood Biomarkers of Brain Injury and Degeneration Following Long-Duration Spaceflight
Peter zu Eulenburg, MD, PhD1; Judith-Irina Buchheim, MD2; Nicholas J. Ashton, PhD, MD3; Galina Vassilieva, MD4; Kaj Blennow, MD, PhD3; Henrik Zetterberg, MD, PhD3; Alexander Choukér, MD2
doi : 10.1001/jamaneurol.2021.3589
JAMA Neurol. 2021;78(12):1525-1527
Association of Targeting Vascular Risk Factors With a Reduction in Dementia Incidence in Old Age
Marieke P. Hoevenaar-Blom, PhD1,2,3; Edo Richard, MD1,3; Eric P. Moll van Charante, MD1,4; Lennard L. van Wanrooij, PhD2; Wim B. Busschers, PhD4; Jan W. van Dalen, PhD1,2,3; Wim A. van Gool, MD1
doi : 10.1001/jamaneurol.2021.3542
JAMA Neurol. 2021;78(12):1527-1528
Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis
Giulio Disanto, MD, PhD1; Rosaria Sacco, MD, PhD1; Enos Bernasconi, MD2,3,4; Gladys Martinetti, MD5; Franco Keller, MD, PhD5; Claudio Gobbi, MD1,3; Chiara Zecca, MD1,3
doi : 10.1001/jamaneurol.2021.3609
JAMA Neurol. 2021;78(12):1529-1531
Visual Neglect After an Isolated Lesion of the Superior Colliculus
Thomas Nyffeler, MD1,2,3; Brigitte C. Kaufmann, PhD1,4; Dario Cazzoli, PhD1,2,5
doi : 10.1001/jamaneurol.2021.3863
JAMA Neurol. 2021;78(12):1531-1533
